Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian 20014, Spain; Biodonostia, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group; Osakidetza Basque Health Service, Microbiology Department, Donostialdea Integrated Health Organisation, Donostia-San Sebastian 20014, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Intensive Care Unit, Donostia University Hospital, Donostia-San Sebastian 20014, Spain.
Eur J Intern Med. 2024 Jan;119:93-98. doi: 10.1016/j.ejim.2023.08.009. Epub 2023 Aug 12.
To evaluate the implementation of an antibiotic stewardship program in critically ill COVID-19 patients and to establish risk factors for coinfection. Secondary objective was to analyze the evolution of the etiology of respiratory nosocomial infections.
Single-center observational cohort study of consecutive patients admitted to ICU due to COVID-19 pneumonia from March 2020 to October 2022. An antibiotic stewardship program was implemented at the end of the second wave.
A total of 878 patients were included during 6 pandemic waves. Empirical antibiotic consumption decreased from the 96% of the patients during the first pandemic wave, mainly in combination (90%) to the 30% of the patients in the 6th pandemic wave most in monotherapy (90%). There were not differences in ICU and Hospital mortality between the different pandemic periods. In multivariate analysis, SOFA at admission was the only independent risk factor for coinfection in critically ill COVID-19 patients (OR 1,23 95%CI 1,14 to 1,35). Differences in bacterial etiology of first nosocomial respiratory infection were observed. There was a progressive reduction in Enterobacteriaceae and non- fermentative Gram Negative Bacilli as responsible pathogens, while methicillin-sensitive Staphylococcus aureus increased during pandemic waves. In the last wave, however, a trend to increase of potentially resistant pathogens was observed.
Implementation of an antibiotic stewardship program was safe and not associated with worse clinical outcomes, being severity at admission the main risk factor for bacterial coinfection in covid-19 patients. A decline in potentially resistant pathogens was documented throughout the pandemic.
评估在 COVID-19 危重症患者中实施抗生素管理计划的情况,并确定合并感染的危险因素。次要目标是分析呼吸道医院感染病因的演变。
这是一项对 2020 年 3 月至 2022 年 10 月期间因 COVID-19 肺炎入住 ICU 的连续患者进行的单中心观察性队列研究。在第二波疫情结束时实施了抗生素管理计划。
在 6 个大流行波期间共纳入了 878 名患者。经验性抗生素使用率从第一波大流行期间的 96%(主要为联合治疗 90%)下降到第六波大流行期间的 30%(主要为单一治疗 90%)。不同大流行期 ICU 和医院死亡率无差异。多变量分析显示,入院时 SOFA 是 COVID-19 危重症患者合并感染的唯一独立危险因素(OR 1.23,95%CI 1.14-1.35)。首次医院获得性呼吸道感染的细菌病因存在差异。肠杆菌科和非发酵革兰阴性杆菌作为主要病原体的比例逐渐下降,而耐甲氧西林金黄色葡萄球菌则在大流行期间增加。然而,在最后一波中,观察到潜在耐药病原体增加的趋势。
实施抗生素管理计划是安全的,与较差的临床结果无关,入院时的严重程度是 COVID-19 患者发生细菌合并感染的主要危险因素。在整个大流行期间,记录到潜在耐药病原体的下降。